RANDOMIZED PHASE-II TRIAL COMPARING 2 CHEMOTHERAPY COMBINATIONS FOR NONSMALL CELL LUNG-CANCER - MITOMYCIN, IFOSFAMIDE, AND CISPLATIN VERSUS VINDESINE, IFOSFAMIDE, AND CISPLATIN

被引：4

作者：

BARON, MG

ARTAL, A

GARRIDO, P

GIRON, CG

ORDONEZ, A

FELIU, J

BERROCAL, A

BARON, JM

机构：

[1] Servicio de Oncologia, Hospital La Paz, 28046 Madrid

来源：

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 1993年 / 16卷 / 04期

关键词：

ADVANCED NONSMALL CELL LUNG CANCER; AMBULATORY CHEMOTHERAPY;

D O I：

10.1097/00000421-199308000-00006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Two chemotherapy regimens for advanced NSCLC given on an outpatient basis were evaluated in a prospective phase II trial: mitomycin, ifosfamide, and cisplatin (MIP) vs vindesine, ifosfamide, and cisplatin (VIP). This study included 100 patients. Prognostic factors were well balanced between the arms. Objective response rates (CR: MIP 0%, VIP 4%; PR: MIP 24%, VIP 18%) and survival (median time: 7 months in both arms) were in the standard range usually reported. Subjective and symptomatic improvement have been assessed. Toxicity was moderate, manageable, and mostly reversible. We believe that investigation for new ambulatory schemes must continue.

引用

页码：310 / 314

页数：5

共 24 条

[1]

[Anonymous], 1979, WHO HDB REPORTING RE

[2]

ARTAL A, 1990, P AN M AM SOC CLIN, V9, P253

[3]

GATZEMEIER N, 1985, 4TH P WORLD C LUNG C

[4]

GIRON CG, 1987, CANCER TREAT REP, V71, P851

[5]

GORDON CJ, 1989, CANCER, V63, P578, DOI 10.1002/1097-0142(19890201)63:3<578::AID-CNCR2820630330>3.0.CO

[6]

2-Z

[7]

GRALLA RJ, 1988, SEMIN ONCOL, V15, P2

[8] COUNTING THE COSTS OF CHEMOTHERAPY IN A NATIONAL-CANCER-INSTITUTE-OF-CANADA RANDOMIZED TRIAL IN NONSMALL-CELL LUNG-CANCER [J].

JAAKKIMAINEN, L ;

GOODWIN, PJ ;

PATER, J ;

WARDE, P ;

MURRAY, N ;

RAPP, E .

JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (08) :1301-1309

[9]

JOSS RA, 1990, CANCER, V65, P2426, DOI 10.1002/1097-0142(19900601)65:11<2426::AID-CNCR2820651104>3.0.CO

[10]

2-3

← 1 2 3 →